Novo Holdings’ portfolio company LAVA Therapeutics goes public

Novo Holdings’ portfolio company LAVA Therapeutics goes public

Date
March 24, 2021

Novo Holdings would like to congratulate our portfolio company LAVA Therapeutics (Nasdaq: LVTX) on their recent IPO. LAVA Therapeutics is a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy.

For further information, please find the full statement here.